LY75-CD302

Across TCGA pan-cancer cohorts, LY75-CD302 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated LY75-CD302 data layer compared with 1 for mutation status.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher LY75-CD302 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated LY75-CD302 expression acts as an unfavorable survival marker, although some lineages such as SKCM and LUAD show a favorable association.

SKCM, ACC, and MESO are the cancer types where LY75-CD302 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.624	0.419	<.001	90	view →
ACC	OS	Tertile	All	0.638	0.901	<.001	85	view →
MESO	OS	Median	IV	0.252	0.748	.002	75	view →
PAAD	DFS	Tertile	All	0.155	0.426	<.001	60	view →
LGG	OS	Quartile	All	0.351	0.472	.001	26	view →
COAD	OS	Quartile	All	0.773	0.912	.015	20	view →
READ	DFS	Tertile	IV	0.190	0.772	<.001	19	view →
LUAD	DFS	Tertile	III,IV	0.978	0.586	.002	18	view →
THCA	DFS	Median	All	0.759	0.907	.002	15	view →
STAD	DFS	Tertile	III,IV	0.297	0.523	.011	12	view →
KIRC	DFS	Quartile	III,IV	0.835	0.555	.017	10	view →
LIHC	DFS	Tertile	III,IV	0.485	0.321	.049	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

LY75-CD302–SKCM (DFS)

Open the SKCM breakdown →